Dynavax Technologies Corp. will be paid $6 million for starting human testing of a potential lupus treatment.
Berkeley-based Dynavax (NASDAQ: DVAX) will get the payment from GlaxoSmithKline (NYSE: GSK), its partner on this project.
This is a Phase I trial, mainly to test the safety of the treatment, DV1179, which inhibits two Toll-like receptors, or TLRs, which affect the body’s inflammatory response.
No comments:
Post a Comment